No abstract available.
Anemia, Aplastic*

No abstract available.
Diabetic Retinopathy* ; Retina*

Rotator cuff tear is a common reason for shoulder pain. Although the surgical technique of rotator cuff repair is developing, high retear rate requires additional supplementary methods. Among these supplementary methods, as a kind of biologic augmentation, platelet-rich plasma (PRP) has been spotlighted and has recently been studied by many researchers. PRP, a concentrate of platelet extract obtained from whole blood, contains numerous growth factors. As this is known to play an important role in the tissue recovery process, it had been used for research in a variety of fields including orthopedics. Use of PRP has been attempted in surgical treatments of rotator cuff tear for better results; however, only a few large-scale research studies on the effect of PRP have been reported. Clinical results of each study are also variable. Therefore research using large-scale randomized, double-blind trials should be conducted in order to prove the application range, safety, and clinical effects of PRP.
Blood Platelets ; Intercellular Signaling Peptides and Proteins ; Orthopedics ; Platelet-Rich Plasma* ; Rotator Cuff* ; Shoulder ; Shoulder Pain

PURPOSE:Short stature relative to the familial height potential is a universial characteristics of patients with Turner syndrome. growth hormone(GH)therapy has been shown to improve adult height in Turner syndrome. this study was done to determine the effects of GH treatment. Objects and METHOD:178 patients were enrolled by investigators at multiple center. Diagnosis of Turner syndrome confirmed by karyotype analysis. Growth rate of 121 patients who were given Recombinant human GH(0.6-1.0IU/kg/Week) by subcutaneous injection for 1-3 years were analized. Final adult height was defined by the growth rate which was less than 1cm/year. RESULTS:Height velocity increased significantly during GH treatment, particularly in the first year. mean height velocity of our Turner patients was 6.3(+/-.39)cm/year during the first year(121 patients), 5.3(+/-.72)cm/year during second year(92 patients), 4.6(+/-.62)cm/year during third year(72 patients) after GH treatment. Mean height velocity of our Turner patients without GH treatment was 3.8(+/-.47)cm/year. the final adult height of our Turner patients with GH trearment was 143.0(+/-.6)cm. the final adult height without GH trearment was 139.6(+/-.9)cm. CONCLUSION: Our data demonstrate that GH treatment seems effective in accelerating growth velocity and in improving final height in Turner syndrome. the final height of our Turner patients is not to be considered the best result, as most of them was received GH therapy late age.
Adult ; Diagnosis ; Female* ; Growth Hormone* ; Humans ; Injections, Subcutaneous ; Karyotype ; Research Personnel ; Turner Syndrome*

In order to study the effect of lead exposure on the hematocrit and hemoglobin values in accordance with the level of lead exposure, twenty-four Sprague-Dawly rates were equally divided into four groups of six tars each. Lead acetate disolved in glucose was injected intrapertitoneally six times a week, for weeks with does of 0.05 mg/kg/day for group I, 0.5 mg/kg/day for group II, and 5 mg/kg/day for group III. Control group was injected glucose only. Blood samples for the checking of the hematocrit and hemoglobin values, were taking from tail vein of rats before lead injection and on the third, seventh, fourteenth, twenty-first, and twenty-eighth days after lead injection. And also, the concentration of lead and ALA in urine were checked for evaluating the lead absorption. The results were as follows ; 1. The alteration of the hematocrit and hemoglobin values of the group I was not significant as that of the control group. 2. In group II, the hematocrit values were significantly decreased from the fourteenth day after lead injection, and the hemoglobin values were decreased from the twenty- first day after lead injection when the concentration of lead in urine was elevated more than 260 microgram/liter. 3. In group III, the hematocrit value were decreased from the seventh day after lead injection, and the hemoglobin value were decreased even from third day after lead injection. And the hemoglobin values were more rapidly decreased than the hematocrit values. 4. In all group, the correlation coefficient between hematocrit and hemoglobin was highly significant. And the difference between the correlation coefficient of the group III and that of the others was highly significant.
Absorption ; Animals ; Glucose ; Hematocrit* ; Rats ; Tars ; Veins

No abstract available.
Diabetes Mellitus* ; Stents*

No abstract available.
Problem-Based Learning*

No abstract available.

No abstract available.
Electronics ; Electrons ; Publications

No abstract available.
Anti-Infective Agents* ; Pneumonia*